Circulating tumor cell count as a biomarker of a specific gastric cancer subgroup characterized by bone metastasis and/or disseminated intravascular coagulation - an early indicator of chemotherapeutic response

Inoue,Masahiro; Otsuka,Kazunori; Shibata,Hiroyuki

doi:10.3892/ol.2015.4056

Circulating tumor cell count as a biomarker of a specific gastric cancer subgroup characterized by bone metastasis and/or disseminated intravascular coagulation - an early indicator of chemotherapeutic response

Authors:
- Masahiro Inoue
- Kazunori Otsuka
- Hiroyuki Shibata
View Affiliations

Affiliations: Department of Clinical Oncology, Graduate School of Medicine, Akita University, Akita 010-8543, Japan
Published online on: December 24, 2015 https://doi.org/10.3892/ol.2015.4056
Pages: 1294-1298
Copyright: © Inoue et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of gastric cancer coupled with multiple bone metastases, and/or disseminated intravascular coagulation (DIC), is characterized by the clinical presentation of rapid progression and a poor prognosis, and differs from typical gastric cancers. Circulating tumor cells (CTCs) are negligible in typical advanced gastric cancers, however, a considerable number of CTCs in the bloodstream may be detected in the subgroup demonstrating multiple bone metastases and/or DIC. The present study analyzed two cases, with the first case regarding a 51‑year‑old male who exhibited a CTC count of 275 cells/7.5 ml following an initial, ineffective, chemotherapy cycle. The patient underwent a second chemotherapy course that was effective, and the cell count was observed to reduced to 2 cells/7.5 ml. A decreased CTC count was first confirmed on day 16 following treatment. During the chemoresistant phase, the CTC count was observed to increase again. The second case presented by the current study describes a 59‑year‑old female who exhibited a CTC count of 235 cells/7.5 ml prior to chemotherapy. This subsequently decreased to 7 cells/7.5 ml following an effective course of chemotherapy. Notably, the CTC count increased alongside disease progression in this case. Within the rare subgroup of gastric cancer patients with multiple bone metastases and/or DIC, CTC count may serve as an early biomarker allowing the evaluation of therapeutic efficacy. However, due to the aggressive nature of this type of cancer, imaging analysis is not recommended as it may typically take several months to complete.

View Figures

View References

1	Yoshikawa K and Kitaoka H: Bone metastasis of gastric cancer. Jpn J Surg. 13:173–176. 1983. View Article : Google Scholar : PubMed/NCBI
2	Silvestris N, Pantano F, Ibrahim T, Gamucci T, De Vita F, Di Palma T, Pedrazzoli P, Barni S, Bernardo A, Febbraro A, et al: Natural history of malignant bone disease in gastric cancer: Final results of a multicenter bone metastasis survey. PLoS One. 8:e744022013. View Article : Google Scholar : PubMed/NCBI
3	Rhee J, Han SW, Oh DY, Im SA, Kim TY and Bang YJ: Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: A retrospective study. J Gastroenterol Hepatol. 25:1537–1542. 2010. View Article : Google Scholar : PubMed/NCBI
4	Takashima A, Shirao K, Hirashima Y, Takahari D, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y and Shimada Y: Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. J Cancer Res Clin Oncol. 136:243–248. 2010. View Article : Google Scholar : PubMed/NCBI
5	Etoh T, Baba H, Taketomi A, Nakashima H, Kohnoe S, Seo Y, Fukuda T and Tomoda H: Diffuse bone metastasis with hematologic disorders from gastric cancer: Clinicopathological features and prognosis. Oncol Rep. 6:601–605. 1999.PubMed/NCBI
6	Etoh T, Baba H, Taketomi A, Nakashima H, Kohnoe S, Seo Y, Saito T and Tomoda H: Sequential methothrextate and 5-fuororacil therapy for diffuse bone metastasis from gastric cancer. Anticancer Res. 18:2085–2088. 1998.PubMed/NCBI
7	Kang BW, Kim JG, Kwon OK, Chung HY and Yu W: Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol. 20:5396–5402. 2014. View Article : Google Scholar : PubMed/NCBI
8	Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, et al: Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: A randomised phase 3 study. Lancet Oncol. 10:1063–1069. 2009. View Article : Google Scholar : PubMed/NCBI
9	Cao C, Zhang X, Kuang M, Gu D, He M, Chen J and Tang C: Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: A meta-analysis. Cancer Sci. 105:1008–1014. 2014. View Article : Google Scholar : PubMed/NCBI
10	Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, et al: ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 376:687–697. 2010. View Article : Google Scholar : PubMed/NCBI
11	Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T, Matsuda S, et al: Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 15:3092–3100. 2008. View Article : Google Scholar : PubMed/NCBI
12	Otsuka K, Imai H, Soeda H, Komine K, Ishioka C and Shibata H: Practical utility of circulating tumour cells as biomarkers in cancer chemotherapy for advanced colorectal cancer. Anticancer Res. 33:625–629. 2013.PubMed/NCBI
13	Komine K, Inoue M, Otsuka K, Fukuda K, Nanjo H and Shibata H: Utility of measuring circulating tumor cell counts to assess the efficacy of treatment for carcinomas of unknown primary origin. Anticancer Res. 34:3165–3168. 2014.PubMed/NCBI
14	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
15	Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW and Hayes DF: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351:781–971. 2004. View Article : Google Scholar : PubMed/NCBI
16	Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG and Terstappen LW: Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disease status. Urology. 58:386–392. 2001. View Article : Google Scholar : PubMed/NCBI
17	Koga T, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H and Maehara Y: Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. Hepatogastroenterology. 55:1131–1135. 2008.PubMed/NCBI
18	Toyoshima K, Hayashi A, Kashiwagi M, Hayashi N, Iwatsuki M, Ishimoto T, Baba Y, Baba H and Ohta Y: Analysis of circulating tumor cells derived from advanced gastric cancer. Int J Cancer. 137:991–998. 2015. View Article : Google Scholar : PubMed/NCBI
19	Pantel K and Alix-Panabières C: Bone marrow as a reservoir for disseminated tumor cells: A special source for liquid biopsy in cancer patients. Bonekey Rep. 3:5842014. View Article : Google Scholar : PubMed/NCBI